Academic Journal
Intranasal hybrid nanoparticles encapsulating rizatriptan enhance antimigraine efficacy in an optogenetic spreading depression model.
| Τίτλος: | Intranasal hybrid nanoparticles encapsulating rizatriptan enhance antimigraine efficacy in an optogenetic spreading depression model. |
|---|---|
| Συγγραφείς: | Kaya MZ; Neurovascular Research Unit, Massachusetts General Hospital, Boston, MA, USA; Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey., Gultekin Y; Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey., Celebier M; Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey., Soyseven M; Anadolu University, Yunus Emre SHMYO, Department of Analytical Chemistry, Eskisehir, Turkey., Vural I; Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey., Oner L; Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey., Ayata C; Neurovascular Research Unit, Massachusetts General Hospital, Boston, MA, USA., Pehlivan SB; Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey. Electronic address: sbozdag@hacettepe.edu.tr., Harriott AM; Neurovascular Research Unit, Massachusetts General Hospital, Boston, MA, USA. |
| Πηγή: | International journal of pharmaceutics [Int J Pharm] 2026 Apr 10; Vol. 694, pp. 126743. Date of Electronic Publication: 2026 Mar 05. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press. |
| Ιατρικοί όροι (MeSH): | Nanoparticles*/chemistry , Nanoparticles*/administration & dosage , Tryptamines*/administration & dosage , Tryptamines*/pharmacokinetics , Tryptamines*/chemistry , Tryptamines*/pharmacology , Cortical Spreading Depression*/drug effects , Migraine Disorders*/drug therapy , Migraine Disorders*/physiopathology, Polylactic Acid-Polyglycolic Acid Copolymer/chemistry ; Calcitonin Gene-Related Peptide/administration & dosage ; Calcitonin Gene-Related Peptide/chemistry ; Hyperalgesia/drug therapy ; Brain/metabolism ; Brain/drug effects ; Animals ; Administration, Intranasal ; Male ; Mice ; Drug Liberation ; Disease Models, Animal ; Mice, Inbred C57BL ; Delayed-Action Preparations ; Triazoles |
| Περίληψη: | Cortical spreading depression (SD) is the likely cause of migraine aura and a putative headache trigger. Migraine treatments, including triptans and calcitonin gene related peptide (CGRP) receptor antagonists, are limited by poor bioavailability. This study evaluates whether intranasally administered poly lactic co-glycolic acid (PLGA) based hybrid nanoparticles (HNPs) encapsulating rizatriptan (RZT) could provide sustained drug release, enhance brain delivery, and improve therapeutic efficacy against periorbital allodynia triggered by optogenetic SD in mice. CGRP (Copyright © 2026 Elsevier B.V. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Given their role as International Journal of Pharmaceutics, Andrea M. Harriott serves on the Board of Directors of the American Headache Society, AmericanMigraine Foundation and Headache Cooperative of New England, has served on Scientific Advisory Boards for Theranica and Abbvie. Melih Z. Kaya and Yakup Gultekin are former co-founders of Nanomy LLC. Mustafa Celebier, Murat Soyseven, Imran Vural, Levent Oner, Cenk Ayata and Sibel Bozdag Pehlivan don’t have anything to declare. |
| References: | Headache. 2006 Jun;46 Suppl 1:S3-8. (PMID: 16927957) Int J Biol Macromol. 2017 Mar;96:687-696. (PMID: 28041915) Handb Clin Neurol. 2010;97:99-108. (PMID: 20816413) Cephalalgia. 2021 Mar;41(3):329-339. (PMID: 33059476) J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Apr 25;787(2):415-9. (PMID: 12650763) Cephalalgia. 2018 Jan;38(1):1-211. (PMID: 29368949) Pain. 2005 May;115(1-2):1-4. (PMID: 15836963) Neurosci Lett. 1993 Mar 5;151(1):13-6. (PMID: 8385759) Nat Rev Drug Discov. 2021 Feb;20(2):101-124. (PMID: 33277608) Ann Neurol. 2004 Jan;55(1):27-36. (PMID: 14705109) Eur J Pharmacol. 1997 Jun 5;328(1):37-40. (PMID: 9203565) Headache. 2025 Feb;65(2):315-325. (PMID: 39364589) J Neurosci. 1993 Mar;13(3):1167-77. (PMID: 8382735) Ann Neurol. 2004 Jan;55(1):19-26. (PMID: 14705108) RSC Adv. 2021 Dec 20;12(1):319-325. (PMID: 35424498) J Pharmacol Exp Ther. 1990 Jul;254(1):123-8. (PMID: 2164085) J Neurosci. 2010 Jun 30;30(26):8807-14. (PMID: 20592202) Am J Physiol Lung Cell Mol Physiol. 2002 Apr;282(4):L833-9. (PMID: 11880310) Pharmaceutics. 2022 Jan 26;14(2):. (PMID: 35214019) Int J Biol Macromol. 2022 Aug 31;215:579-595. (PMID: 35779651) Nanomedicine (Lond). 2022 Mar;17(7):447-460. (PMID: 35142565) Pharmaceutics. 2018 May 18;10(2):. (PMID: 29783687) Neuroscience. 1998 Jan;82(2):469-84. (PMID: 9466454) J Neurosci. 2017 Jul 26;37(30):7149-7163. (PMID: 28642283) Int J Biol Macromol. 2020 Jan 1;142:52-62. (PMID: 31593739) J Headache Pain. 2022 Jun 8;23(1):65. (PMID: 35676636) Pharmaceutics. 2024 Apr 01;16(4):. (PMID: 38675142) Pharmaceutics. 2021 Nov 30;13(12):. (PMID: 34959331) Methods Mol Biol. 2007;386:3-55. (PMID: 18604941) J Headache Pain. 2020 Apr 29;21(1):41. (PMID: 32349662) J Control Release. 2018 Jan 10;269:1-9. (PMID: 29061510) Pharmaceutics. 2022 Jul 18;14(7):. (PMID: 35890379) J Control Release. 2017 Sep 10;261:187-198. (PMID: 28684169) Cephalalgia. 2024 Aug;44(8):3331024241252666. (PMID: 39133176) Nanomedicine (Lond). 2017 Jul;12(13):1533-1546. (PMID: 28621578) Neurology. 2001 Oct 23;57(8):1377-83. (PMID: 11673575) J Headache Pain. 2023 Jul 19;24(1):85. (PMID: 37464297) Biomed Chromatogr. 2006 Jan;20(1):61-6. (PMID: 15954161) Headache. 2019 Sep;59(8):1310-1323. (PMID: 31410844) Nanomedicine (Lond). 2016 Mar;11(6):673-92. (PMID: 27003448) Curr Med Chem. 2019;26(35):6459-6492. (PMID: 31453778) Headache. 2021 Mar;61(3):438-454. (PMID: 33594686) Cephalalgia. 2011 Apr;31(6):748-50. (PMID: 21383046) Clinicoecon Outcomes Res. 2021 Jul 14;13:647-660. (PMID: 34285524) Pain. 2008 Oct 31;139(3):533-540. (PMID: 18723285) ACS Appl Mater Interfaces. 2023 Dec 13;15(49):56749-56759. (PMID: 38015621) iScience. 2023 Oct 06;26(11):108153. (PMID: 37867938) J Control Release. 2013 Dec 28;172(3):662-70. (PMID: 24021356) Neurotherapeutics. 2018 Apr;15(2):304-312. (PMID: 29556965) Exp Neurol. 1998 Mar;150(1):45-51. (PMID: 9514827) J Pharm Sci. 2015 May;104(5):1709-20. (PMID: 25716582) J Sci Food Agric. 2024 Aug 15;104(10):5846-5859. (PMID: 38385802) Int J Pharm X. 2019 Aug 13;1:100030. (PMID: 31517295) Br J Clin Pharmacol. 1998 Dec;46(6):577-82. (PMID: 9862247) Nat Methods. 2010 Jun;7(6):447-9. (PMID: 20453868) J Basic Clin Pharm. 2016 Mar;7(2):27-31. (PMID: 27057123) Mater Sci Eng C Mater Biol Appl. 2015 Jan;46:514-20. (PMID: 25492016) Brain Res Bull. 2020 Feb;155:184-190. (PMID: 31790722) Pharm Nanotechnol. 2018;6(2):81-93. (PMID: 29886842) J Neurosci. 1999 May 1;19(9):3423-9. (PMID: 10212302) Pain. 2013 Aug;154(8):1254-62. (PMID: 23673147) Chem Rec. 2016 Aug;16(4):1833-51. (PMID: 27258402) Int J Mol Sci. 2022 Apr 09;23(8):. (PMID: 35456971) Drug Deliv. 2013;20(1):47-56. (PMID: 23311653) Pharmazie. 2011 Mar;66(3):171-7. (PMID: 21553646) J Nanosci Nanotechnol. 2016 Feb;16(2):1339-45. (PMID: 27433584) Pharmaceutics. 2022 Mar 05;14(3):. (PMID: 35335948) Cephalalgia. 2014 Apr;34(4):258-67. (PMID: 24108308) Ann Neurol. 2009 Feb;65(2):184-93. (PMID: 19259966) Eur J Pharm Biopharm. 2014 Oct;88(2):529-38. (PMID: 25119723) Br J Pharmacol. 1993 Jul;109(3):788-92. (PMID: 8395298) Pain. 2023 Nov 1;164(11):2564-2571. (PMID: 37318029) Cephalalgia. 2004 Jan;24(1):2-11. (PMID: 14687006) Respir Res. 2009 Feb 03;10:8. (PMID: 19192276) Expert Opin Pharmacother. 2000 Mar;1(3):391-404. (PMID: 11249525) Molecules. 2022 Feb 09;27(4):. (PMID: 35208958) J Pharm Biomed Anal. 2006 Jun 16;41(4):1146-51. (PMID: 16563688) Headache. 2016 Nov;56(10):1635-1648. (PMID: 27731896) Pharmaceutics. 2023 Jun 03;15(6):. (PMID: 37376097) Nat Commun. 2022 Feb 3;13(1):646. (PMID: 35115501) Mol Pharm. 2021 Aug 2;18(8):3132-3146. (PMID: 34259534) Nanomedicine (Lond). 2018 Jul;13(13):1513-1516. (PMID: 29998779) AAPS PharmSciTech. 2024 Jul 1;25(6):152. (PMID: 38954218) Int J Nanomedicine. 2017 Sep 08;12:6687-6704. (PMID: 28932114) Biomedicines. 2022 Jul 14;10(7):. (PMID: 35885011) Int J Mol Sci. 2022 Feb 25;23(5):. (PMID: 35269665) Pak J Pharm Sci. 2020 Jan;33(1):221-228. (PMID: 32122852) PLoS One. 2024 Dec 9;19(12):e0313482. (PMID: 39652533) Nanotechnology. 2017 Jun 23;28(25):255101. (PMID: 28561013) Cephalalgia. 2017 Sep;37(10):979-989. (PMID: 27573009) J Neurosci. 1997 Dec 15;17(24):9545-53. (PMID: 9391009) Ann Neurol. 2021 Jan;89(1):99-110. (PMID: 33016466) Front Pharmacol. 2021 Sep 20;12:713616. (PMID: 34616297) Headache. 2010 Apr;50(4):725-30. (PMID: 20456160) Curr Pharm Des. 2018;24(21):2362-2374. (PMID: 29766785) Nanomaterials (Basel). 2023 Nov 23;13(23):. (PMID: 38063700) J Headache Pain. 2010 Feb;11(1):5-12. (PMID: 20012125) Int J Pharm. 2007 Jun 7;337(1-2):155-60. (PMID: 17267150) Int J Pharm. 2022 Nov 25;628:122278. (PMID: 36243325) Biomedicines. 2021 May 20;9(5):. (PMID: 34065544) Eur J Pharmacol. 2022 May 5;922:174902. (PMID: 35358493) Ann Neurol. 2004 Sep;56(3):371-81. (PMID: 15349864) Int J Mol Sci. 2021 Mar 10;22(6):. (PMID: 33801871) Front Mol Neurosci. 2017 Sep 06;10:284. (PMID: 28932184) Drug Des Devel Ther. 2017 Jun 19;11:1815-1825. (PMID: 28684900) J Neurosci. 2012 Oct 31;32(44):15439-49. (PMID: 23115181) Pharmaceutics. 2019 Aug 10;11(8):. (PMID: 31405159) AAPS PharmSciTech. 2022 Dec 16;24(1):20. (PMID: 36526821) Int J Pharm. 2004 May 4;275(1-2):171-87. (PMID: 15081148) Adv Ther. 2020 Dec;37(12):4765-4796. (PMID: 32990921) Pharmaceutics. 2022 Dec 01;14(12):. (PMID: 36559181) Front Pharmacol. 2022 Mar 14;13:855294. (PMID: 35359855) Drug Deliv. 2015;22(7):931-9. (PMID: 24512295) Artif Cells Nanomed Biotechnol. 2017 Dec;45(8):1657-1664. (PMID: 28084837) Front Pharmacol. 2023 Aug 28;14:1227423. (PMID: 37701036) Ann Neurol. 2018 Sep;84(3):409-423. (PMID: 30014540) AAPS PharmSciTech. 2017 Feb;18(2):517-528. (PMID: 27126007) Drug Dev Ind Pharm. 2022 Jan;48(1):21-28. (PMID: 35703403) |
| Grant Information: | K08 NS124991 United States NS NINDS NIH HHS |
| Contributed Indexing: | Keywords: CGRP(8-37); Hybrid nanoparticle; Migraine; Optogenetic cortical spreading depression; Periorbital allodynia; Rizatriptan |
| Substance Nomenclature: | 51086HBW8G (rizatriptan) 0 (Tryptamines) 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) JHB2QIZ69Z (Calcitonin Gene-Related Peptide) 0 (Delayed-Action Preparations) 0 (Triazoles) |
| Entry Date(s): | Date Created: 20260307 Date Completed: 20260710 Latest Revision: 20260813 |
| Update Code: | 20260813 |
| PubMed Central ID: | PMC13174935 |
| DOI: | 10.1016/j.ijpharm.2026.126743 |
| PMID: | 41794348 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1873-3476 |
|---|---|
| DOI: | 10.1016/j.ijpharm.2026.126743 |